Pharmaceutical people first into the Hurun rich list of more than 10 pharmaceutical companies to take the new list

On Oct11, Hurun Research Institute released the 2019 LEXUS Hurun Rich List, ma Yun became China's richest man for the third time with a fortune of 275 billion yuanThis is the 21st release of the Hurun Research Institute "Hurun Rich List", this year's list threshold continues to maintain at 2 billion yuan, a total of 1819 entrepreneurs on the listThis year, for the first time, entrepreneurs in the pharmaceutical industry made the top 10 - Sun Flutter and Zhong Huixuan from Hengrui Pharmaceuticals and Hansen Pharmaceuticals ranked fifth on the list with a fortune of 175 billion yuancompared with other industries, the pharmaceutical industry continued to maintain a steady growth trend, a total of 173 entrepreneurs (families) on the listAmong them, Sun Flutter of Hengrui Pharmaceuticals and Hensen Pharmaceuticals, Mrand MrsZhong Huixuan, Xu Hang of Mei Rui and Peng Rui, Xie Wei of Chinese Bio, Li Xiting of Mei rui, Chen Bang of Eyre Eye, Zhu Bao national family of Healthy Yuan, Xu of Yangzijiang Pharmaceuticals Mirror Man, Hengrui Pharmaceuticals and Hensen Pharmaceuticals' Yu Duda, Xinhua's Chen Fashu, the step-by-step Zhao Tao family, Chung Jin Investment's Chen Jinxia, as well as the drug Ming Kangde Li Ge, Zhao Ning couple and other 12 pharmaceutical-related entrepreneurs (family) into the top 100Sun Flutter, Zhong Huixuan and his wife's ranking this year rose 15 places from last year, into the top 10, and its Hesen Pharmaceuticals listed on the Hong Kong Stock Exchange in June this year has a lot to do with it - directly driving The wealth of Sun Flutter Zhong Huixuan and his wife rose 92.5 billion yuan"Sun Flutter and Zhong Huixuan created a world first, and both husband and wife have created a sizeable independent enterprise, " says Mr Hurun"
statistics, in the first half of this year, Hansen Pharmaceuticals achieved sales revenue of 4.6 billion yuan, an increase of 122 percent from a year earlierAmong them, the main distribution of central nervous system diseases, anti-tumor, anti-infection and other areas, in the first half of 2019 recorded revenue of 1,161 million yuan, 1.843 billion yuan, 965 million yuan and 630 million yuan, respectively, accounting for 25.2%, 40.1%, 21%, 13.7% of total revenueAt present, Henson has five innovative drugs in the clinical phase II and beyond, and has carried out more than 20 human bioequivalence trials (BEs) (including declared production)In the first half of 2019, the company newly declared and obtained 2 clinical approvals, applied for 6 listings, approved 3 new drugs (including 1 innovative drug, 2 first imitation drugs), new through the consistency evaluation of 1Notably, in May this year, Henson also signed a CD19 single anti-inebilizumab cooperation agreement in China to treat spectrum diseases of optic neurospinalitis and other autoimmune diseases and hematologic malignancies, of course, Hengrui Pharmaceuticals, a company with a market capitalisation of 348 billion yuan (as of September 12 this year), achieved revenues of 10 billion yuan in the first half of this year, up 29% year-on-yearIts listed Carrelli Pearl monoantigen, which was approved in May this year, began on September 26 to announce two new indications (single-drug second-line treatment of advanced esophageal squamous cancer, combined pemecosega platinum first-line treatment of advanced or metastatic non-squamous non-small cell lung cancer) to be included in the priority reviewcombined with media disclosure, Sun Said publicly said at the 2019 China Pharmaceutical Entrepreneurs And Scientists Investor conference on October 9th that Hengrui Pharmaceuticals had suspended some generic drug projectsIt is not difficult to see that innovation will be the "richest medicine" of the key weaponthe market environment facing the pharmaceutical industry is changing rapidlyHealth insurance control fees continue, "4 plus 7" band procurement is expanding, the quality of generic drugs and efficacy consistency evaluation to promote enterprises to upgrade thelevel, the national medical insurancedirectory adjustment has entered the normal, the new version of the medical insurance drug catalog adjustment more from clinical needs to consider efficacy and safety, innovative drugs to implement national negotiation access, disease diagnosis-related groups to collect payment (DRGs) national pilot promotion and other policies, all promote the development of the core of the development of powerful pharmaceutical enterprisesthis year's new list of-relatedhome, Junshi biological Xiong Fengxiang, Xiong Jun father and son is one of the examplesTaking Junshi Bio as an example, 19 product pipelines have been successfully discovered and developed or built through cooperative development, 13 of which are innovative drugs developed in chinaIts core product, Toripalimab mono-resistant injection, was approved by the State Drug Administration on December 17, 2018, and is the first domesticped PD-1 monoclonal antibody injection approved for the treatment of local progressorormettomes after previous standard treatment failuresin addition, there are Shi medicine Cai Dongchen, Puli Pharmaceuticalfan Minhua, Zhu Xiaoping couple, Koren Pharmaceuticals' Pan Hui, De
Zhang Zhang Zhang, Osaikang's Chen Qingcai family, Omei Medical's Cui Jinhai family, Kang long into lou Xiaoqiang, Zheng Bei couple, Kang long into lou Boliang, Mabo Pharmaceuticals Guo Jianjun family, Tongze Medical Bao Zhengliang, Du Ying of Ding Pharmaceuticals, Liu Jianhua of Kangchen Pharmaceuticals, Liu Jidong of Xingqi Eye Medicine, Qin Jianfei family of Ha Sanlian, Wu Jinxuan of Goli Pharmaceuticals, Wu Xuexuan of Antu Industrial, Yang Zengli of Antu Industrial, etcare also the faces of this year's new listin addition to , the Li Xianyu family of syringe maker Double Dove rose 1,377 places to a 400 percent fortune And Carbon Cloud and Huada Gene Wang Jun to medical big data, gene testing of the main industry to become the pharmaceutical community in this list of emerging industries the only representative of the person